Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP14 | P54578 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25272072 | 0.87 | GSK3B (0.40) | KDM4EALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL12442952 | 0.82 | EPHX1 (0.41) | SMN1; SMN2POLBPARP14L3MBTL1 | |
| SCHEMBL25281461 | 0.82 | HTR4 (0.39) | KDM4EALDH1A1SMN1; SMN2USP14POLB | |
| SCHEMBL784840 | 0.80 | GAA (0.44) | ALDH1A1SMN1; SMN2POLBPARP14LMNA | |
| SCHEMBL18595476 | 0.80 | POLB (0.40) | ALDH1A1SMN1; SMN2POLBPARP14LMNA | |
| SCHEMBL2607204 | 0.80 | NCF1 (0.41) | ALDH1A1POLBPARP14LMNAL3MBTL1 | |
| SCHEMBL7332383 | 0.79 | HTR4 (0.43) | DRD2DRD4 | |
| SCHEMBL24754129 | 0.79 | TP53 (0.40) | KDM4EALDH1A1SMN1; SMN2USP14POLB | |
| SCHEMBL12788442 | 0.79 | KMT2A (0.37) | USP14POLBPARP14PKMLMNA | |
| SCHEMBL12156690 | 0.79 | PIK3CD (0.41) | KDM4EALDH1A1USP14POLBPARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2023107606-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | KDM4E 971/4885ALDH1A1 1987/4885SMN1; SMN2 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.